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http://www.trialsjournal.com/content/13/1/193STUDY PROTOCOL Open AccessSurgical trial in traumatic intracerebral
hemorrhage (STITCH(Trauma)): study protocol for
a randomized controlled trial
Barbara A Gregson1, Elise N Rowan1*, Patrick M Mitchell1, Andy Unterberg2, Elaine M McColl3, Iain R Chambers4,
Paul McNamee5 and A David Mendelow1Abstract
Background: Intracranial hemorrhage occurs in over 60% of severe head injuries in one of three types: extradural
(EDH); subdural (SDH); and intraparenchymal (TICH). Prompt surgical removal of significant SDH and EDH is
established and widely accepted. However, TICH is more common and is found in more than 40% of severe head
injuries. It is associated with a worse outcome but the role for surgical removal remains undefined. Surgical practice
in the treatment of TICHs differs widely around the world. The aim of early surgery in TICH removal is to prevent
secondary brain injury. There have been trials of surgery for spontaneous ICH (including the STICH II trial), but none
so far of surgery for TICH.
Methods/Design: The UK National Institutes of Health Research has funded STITCH(Trauma) to determine whether
a policy of early surgery in patients with TICH improves outcome compared to a policy of initial conservative
treatment. It will include a health economics component and carry out a subgroup analysis of patients undergoing
invasive monitoring. This is an international multicenter pragmatic randomized controlled trial.
Patients are eligible if: they are within 48 h of injury; they have evidence of TICH on CT scan with a confluent
volume of attenuation significantly raised above that of the background white and grey matter that has a total
volume >10 mL; and their treating neurosurgeon is in equipoise.
Patients will be ineligible if they have: a significant surface hematoma (EDH or SDH) requiring surgery; a
hemorrhage/contusion located in the cerebellum; three or more separate hematomas fulfilling inclusion criteria; or
severe pre-existing physical or mental disability or severe co-morbidity which would lead to poor outcome even if
the patient made a full recovery from the head injury.
Patients will be randomized via an independent service. Patients randomized to surgery receive surgery within 12 h.
Both groups will be monitored according to standard neurosurgical practice. All patients have a CT scan at 5 days
(+/−2 days) to assess changes in hematoma size. Follow-up is by postal questionnaire at 6 and 12 months. The
recruitment target is 840 patients.
Trial registration: Current Controlled Trials ISRCTN19321911
Keywords: Head injury, Traumatic intracerebral hemorrhage, Hematoma, Early surgery* Correspondence: e.n.rowan@ncl.ac.uk
1Neurosurgical Trials Unit, 3–4 Claremont Terrace, Newcastle University,
Newcastle upon Tyne NE2 4AE, UK
Full list of author information is available at the end of the article
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Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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More than 150,000 patients with head injury are admit-
ted to hospital each year in the UK. Of these about
20,000 are serious. One year after a serious head injury
35% of patients are dead or severely disabled. Intracra-
nial hemorrhage occurs in more than 60% of serious
head injuries in one or more of three types: extradural;
subdural; and intraparenchymal. Prompt surgical re-
moval of significant subdural and extradural hemorrhage
is of established and widely accepted value. Intrapar-
enchymal hemorrhage is commoner than both the other
types put together and is found in >40% of severe head
injuries. It is clearly associated with a worse outcome
but the role for surgical removal remains undefined. Sev-
eral terms are used to describe the condition including
traumatic intraparenchymal hemorrhage, traumatic
intracerebral hemorrhage (TICH), and contusion. Our
own prospectively collected data in over 7,000 head-
injured patients in Newcastle has shown that contusions
are more common in older head-injured patients and
can occur in patients with less severe head injury.
Surgical practice in the treatment of TICHs differs
widely. Several issues inform the debate: (a) contused
brain does not recover but appears as encephalomalacic
brain tissue loss on convalescent phase imaging. This
argues that removing TICHs does not increase tissue
loss; (b) Extravasated blood is believed to be neurotoxic
leading to secondary injury that may be avoided by sur-
gical removal; (c) Larger TICHs may be associated with
an ischemic penumbra of brain tissue that could be sal-
vaged; and (d) Some TICHs expand to the point where
they cause mass effect resulting in secondary brain
injury.
The aim of early surgical TICH removal is to prevent
secondary brain injury from these mechanisms. Use of
the operation varies around the world. It is more fre-
quently done in Asia than in Europe or North America.
There have been trials of surgery for spontaneous ICH
(including the ongoing MRC-funded STICH II study
(http://research.ncl.ac.uk/stich/)) but none so far of sur-
gery for TICH. The Cochrane Review (2nd Edition) has
shown benefit from surgical evacuation for spontaneous
supratentorial ICH (SICH) [1]. There are differences in
the pathogenesis, clinical behavior, and outcome for the
two conditions [2]. Patients suffering a TICH tend to be
younger by about 15 years on average than patients suf-
fering a spontaneous ICH and therefore the level of dis-
ability may have a large effect on their ability to return
to work and their economic output. Traumatic ICHs are
more likely to be lobar, to be superficial, and to have a
medium-sized volume (25 to 65 cc). These differences
between the conditions mean that we cannot derive the
role of surgery for TICH from results of the 13 pub-
lished trials of surgery for spontaneous ICH but theSTICH trial showed a trend towards better outcome
with surgery for the group of spontaneous supratentorial
ICH that are most like TICH: superficial hematomas
with no intraventricular bleed [3].
We already know that surgery is effective in patients
with traumatic EDH and SDH and that early surgery is
better than delayed. This is not known for TICH. If early
surgery is of benefit to these patients, then implementa-
tion of early referral and diagnosis with immediate treat-
ment may reduce death and disability in this specific
group of head-injured patients.
Several authors [4-6] have compared surgery with con-
servative treatment in single center retrospective series
and recommended surgery for larger TICHs even if
patients were in an apparently good clinical state ini-
tially. Matheisen et al. [4] found that patients with an
admission Glasgow Coma Score of at least 6 and a lesion
volume of at least 20 mL who had surgery without previ-
ous neurological deterioration had significantly better
outcomes than those who did not have surgery or had
surgery after deterioration. None of the patients who
had surgery before any deterioration died or were vege-
tative as opposed to 39% of those who had surgery after
deterioration and 50% of those who did not have sur-
gery. Choksey et al. [5] found that 38% of patients with
a low GCS and a volume of the TICH >16 mL who had
surgery had a poor outcome compared to 56% of those
who did not have surgery. Zumkeller et al. [6] found
that the poor outcome rate in the operated patients was
29% compared to 59% in the non-operated group. Such
associations do not represent true causes and effects or
treatment benefits or harm.
Boto et al. [7] evaluated the characteristics of severely
head-injured patients with basal ganglia TICH and found
that they tended to enlarge in the acute post-traumatic
period. They found that patients with a TICH of >25 mL
and those in whom TICH enlargement or raised intra-
cranial pressure had occurred had the worst outcomes.
They suggested that these patients might benefit from
more aggressive surgical treatment.
D’Avella et al. [8] published a series and suggested that
non-comatose patients with smaller TICHs may be trea-
ted conservatively but that surgery is indicated for
patients with larger TICHs. Most of their comatose
patients who were severely injured had a poor outcome
whatever treatment was used.
None of these studies involved randomization into sur-
gical and non-surgical groups. They also differed in the
characteristics of the parenchymal blood. Such uncon-
trolled observational studies are potentially misleading
and a randomized controlled trial is needed otherwise
the wrong conclusion could be drawn.
Guidelines for the Surgical Management of Traumatic
Brain Injury were published in 2006 in Neurosurgery
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area have been observational and there is a lack of Class
1 evidence from well-designed randomized controlled
trials [9]. Those studies that attempt to compare out-
come between surgical and non-surgical groups cannot
adequately control for known prognostic variables.
NICE have recommended in the Head Injury Update
Full Guideline (2007) that research is needed to develop
a consensus on criteria for lesions not currently consid-
ered to be surgically significant: namely TICH. This trial
(STITCH(TRAUMA)) has been recommended by the
latest NICE Head Injury Guideline Development Group.
This study (STITCH(TRAUMA)) is to evaluate the
role of early surgical removal of traumatic intracerebral
hematomas.
Objectives
To determine whether a policy of early surgery in
patients with traumatic intracerebral hemorrhage
improves outcome compared to a policy of initial con-
servative treatment.
To assess the relative costs and consequences of early
surgery versus conservative management in UK patients
and those in a subgroup of countries covering the likely
highest recruiting centers.
To confirm appropriate thresholds for intracranial
pressure (ICP) and cerebral perfusion pressure (CPP) for
clinical management of head-injured patients with TICH
in the subgroup of patients with such monitoring.
Methods/Design
Trial design
The Surgical Trial in Traumatic Intracerebral Haemor-
rhage (STITCH(TRAUMA)) is an international multi-
center pragmatic randomized parallel group trial
comparing early surgical evacuation of TICH with initial
conservative treatment. Only patients for whom the
treating neurosurgeon is in equipoise about the benefits
of early surgical evacuation compared to initial conser-
vative treatment are eligible for the trial. An independent
24-h telephone and web randomization service based in
the Aberdeen Clinical Trials Unit is used. This is backed
up by 24-h availability of Trial Investigators who can ad-
vise on patient eligibility. Random allocation ensures
that the two groups are balanced within a geographic re-
gion with a minimization algorithm based on age and se-
verity. Outcome is measured at 6 and 12 months via a
postal questionnaire using the extended Glasgow Out-
come Scale.
Additional data is collected in those centers that prac-
tice invasive brain monitoring of intracranial pressure
(ICP) and cerebral perfusion pressure (CPP) to see if
there is evidence that such monitoring techniques add
value to clinical decision-making. This will give anunbiased assessment of the effect of clot removal or not
on ICP/CPP. This analysis will help to evaluate whether
monitoring ICP/CPP provides additional information
that informs better clinical management (the third ob-
jective). Such monitoring is not mandatory for a patient
to be enrolled in the trial.
Relevant healthcare costs will be assessed in the UK
including length of hospital stay and the costs associated
with surgical treatment (theater time, consumables,
overheads); healthcare resource use outside of hospital
(for example, district nurse, physiotherapy) together with
productivity costs arising from absence from work; and
additional costs for family members through extra caring
responsibilities. Consequences will be measured by com-
bining data on quality of life, measured using the EQ-5D
with survival to generate Quality Adjusted Life Years
(QALYs).Screening logs
Screening logs are maintained by each participating cen-
ter to record: the patients admitted to the neurosurgical
unit with any traumatic ICH; whether they are eligible
for the trial or not and whether they are recruited or not
(and if not, why not, if the reason can be ascertained).
These will be used to provide a context for the study, to
monitor recruitment rates, and as the basis for con-
structing the CONSORT diagram for reporting the trial.Center eligibility
The centers recruited are those already collaborating
successfully with the team in other studies (STICH,
STICH II, RescueICP) plus those identified by the vari-
ous networks: TARN (Trauma Audit and Research Net-
work), EBIC (European Brain Injury Consortium) and
EMN (Euroacademia Multidisciplinaria Neurotraumato-
logica), BrainIT, EANS (European Association of Neuro-
surgical Societies), GNAMED (Scottish and Newcastle
Neurosurgery Research Group), SBNS (Society of British
Neurological Surgeons), and BNRG (British Neurosur-
gery Research Group).
Only centers that can demonstrate effective trial ex-
perience and previous adherence to trial guidelines with
high follow-up rates are eligible to take part. In order to
be eligible a center must be able to recruit a minimum
of one patient per year. They must be able to communi-
cate with the research team. (At least one member of
the local team must be proficient in English and provide
contact details where they can be reached easily to sup-
port the local center and respond to the trial manage-
ment team in Newcastle.) They must be able to provide
CT scans of sufficient quality to the study centre in
Newcastle. They must be able to arrange follow-up for
patients with limited literacy.
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other permissions as needed to conform with local and
national legislation and research governance frameworks
and to provide documentary evidence to the trial man-
agement team that these permissions are in place, prior
to site registration and initiation. Each site is also required
to sign an agreement with the sponsor (Newcastle upon
Tyne Hospitals NHS Foundation Trust) and the contrac-
tor (Newcastle University). Applications by the lead col-
laborator in each center for ethical approval (or SSA in
the UK) are supported by the trial manager and the clin-
ical lead for the center and country in which the center is
located. Also within the UK, R&D approval is sought in
respect of all participating centers and the study is open to
audit (‘for cause’ or as part of the routine 10% check) by
the appropriate research governance teams in the partici-
pating Trusts. A member of the study team visits centers
with high volume recruitment or where there are con-
cerns about patient eligibility (identified by central moni-
toring) to confirm patient existence and monitor
adherence to the trial protocol, against pre-determined,
risk-based criteria (we do not anticipate conducting 100%
site data verification).
Approval to start
MREC approval for the study was obtained from
Southampton Multicentre Research Ethics Committee.
Appropriate local ethical approval is sought from each
participating center in the study with proof of the
approval forwarded to the trial coordinating office before
recruitment can be started. The trial is conducted
according to local ethical and Research and Develop-
ment procedures. An agreement is signed between the
sponsor (Newcastle upon Tyne NHS Hospitals Founda-
tion Trust), the holder of the study funding (Newcastle
University) and the hospital center prior to commencing
the study at the center.
Patient recruitment
All appropriate patients who are considered for STITCH
(TRAUMA) must have a CT scan to confirm the diagno-
sis and the size and location of the hematoma. Any clot-
ting or coagulation problems must be corrected prior to
randomization in line with standard clinical practice.
Inclusion criteria
 Adults aged 14 years or over
 Evidence of a TICH on CT with a confluent volume
of attenuation significantly raised above that of the
background white and grey matter that has a total
volume >10 mL calculated by (width × height ×
length)/2 in cm
 Within 48 h of head injury Clinical equipoise: only patients for whom the
responsible neurosurgeon is uncertain about the
benefits of either treatment are eligibleExclusion criteria
 A significant surface hematoma (EDH or SDH)
requiring surgery (the indications for intervention
for these patients are already very well defined)
 Three or more separate hematomas fulfilling
inclusion criteria
 If the hemorrhage/contusion is located in the
cerebellum
 If surgery cannot be performed within 12 h of
randomization
 Severe pre-existing physical or mental disability or
severe co-morbidity which would lead to a poor
outcome even if the patient made a full recovery
from the head injury (examples would be a high
level of dependence before the injury or severe
irreversible associated injury such as complete spinal
cord injury)
 Permanent residence outside a study country
preventing follow-up
 Patient and/or relative has a strong preference for
one treatment modality
There is no specified upper age limit. The need for
clinical equipoise and explicit exclusion of patients with
severe pre-existing physical or mental disability or severe
co-morbidity which might lead to a poor outcome even
if the patient made a good recovery from the head injury
excludes the older less able patient while allowing a fit
older person to be included. Hematoma rates are known
to be more common in the older head-injured patient.Consent procedure
Written witnessed informed consent of the patient or
relative must be obtained by trained neurosurgical staff
prior to randomization. The member of neurosurgical
staff provides a written information sheet and allows as
much time as possible to discuss the options. One copy
of the consent form is given to the patient, one is filed
in the patient notes, and one is filed with the trial docu-
mentation. If the patient is unable to give consent them-
selves due to the nature of the hemorrhage a personal
representative is approached to give consent on behalf of
the patient. The personal representative is the person
with a close personal relationship with the patient who
is themselves capable and willing to consent on behalf of
the patient. (If the patient is unable to consent and the
closest relative is not available the patient cannot be
included in the study.)*
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be obtained from the welfare guardian or, if there is
none, from the nearest relative.Randomization (treatment allocation)
Before randomization, a one-page form is completed by
the responsible neurosurgeon recording demographic
(age, gender) and TICH characteristics (site, side, ABC
measures to define volume) and status at randomization
(pupils equal and reacting or not). The clinician either
telephones the independent 24-h telephone random-
ization service or accesses the randomization website
and enters the randomization information. At the end of
the randomization phone call/web data entry process
the neurosurgeon is informed of the patient identifier
number for the trial and the treatment group the patient
is allocated to. The neurosurgeon records this informa-
tion on the randomization form and then faxes the form
to the STITCH(TRAUMA) Office. If the site has pro-
blems contacting the randomization service they are able
to contact a member of the project team using the study
backup number.
The data manager checks this information against the
information received from the randomization center and
enters the data into an anonymized password protected
database. A list of patient names and study numbers are
kept in a separate file to ensure patient confidentiality is
maintained.
Allocation is stratified by geographic region, with a
minimization algorithm based on age group and severity
(as measured by whether the pupils are equal and react-
ing or not) and with a random component (that is, with
probability of 80%).Trial interventions
The two trial interventions are: (1) early evacuation of
the hematoma by a method of the surgeon’s choice
(within 12 h of randomization), combined with appro-
priate best medical treatment; or (2) best medical
treatment combined with delayed (>12 h after
randomization) evacuation if it becomes appropriate
later. Both groups are monitored according to stand-
ard neurosurgical practice.
If the patient is randomized to early surgery this
should be undertaken as soon as possible and within 12 h
of randomization.
Best medical treatment may include (depending on the
practices within the center) monitoring of ICP or other
modalities and management of metabolism, sodium os-
motic pressure, temperature, and blood gasses.
All patients also have an additional CT scan at about 5
days (+/−2 days) to assess changes in the hematoma size
with and without surgery. This will enable us todemonstrate the proportion of the clot removed by sur-
gery or the changes in volume of the clot without
surgery.
Compliance
Patients or their relatives may withdraw consent for an
operation, or conversely request an operation after
randomization, thereby leading to crossover between the
arms. These are rare events but in surgical trials it is
common for the patient’s condition to change over time
and a patient randomized to initial conservative treat-
ment may deteriorate and require surgery later. Such
crossovers and the reasons for them are documented.
Information is collected about the status (GCS and focal
signs) of patients through the first 5 days of their trial
progress and ICP/CPP measures in invasively monitored
patients in order to be able to describe the change in
status that leads to a change in equipoise for the treating
neurosurgeon, and subsequent surgery in patients ini-
tially randomized to conservative treatment.
Compliance with treatment allocation is monitored by
the data manager.
In surgical trials patients allocated to the non-surgical
arm of the trial may later deteriorate and surgeons may
intervene. This was the case in the MRC-funded STICH
trial [3], in trials of cardiac surgery compared with
angioplasty, in the MRC-funded back pain trial [10] and
in the SPORT trials [11]. These crossover rates to sur-
gery were 26%, 28%, 28%, and 30%, respectively. While
surgical trials will always have such crossovers when sur-
geons perceive that there is value in operating on
patients who deteriorate after initial randomization into
the conservative limb of the trial, we must understand,
monitor, and report the rates of such crossovers.
The aim is to achieve as high compliance as possible
but experience and the above literature suggest that it is
neither practical nor ethical to have 100% compliance
with conservative treatment. During the recruitment of
centers and at investigator meetings the importance of
clinical equipoise and minimizing crossovers is empha-
sized and any crossover occurring within 12 h of
randomization is investigated. Centers exhibiting high
crossover rates may be withdrawn from the study.
Data collection
To preserve confidentiality all patients are allocated a
unique study identifier during the randomization process
which is used on all data collection forms and question-
naires. Only a limited number of members of the re-
search team are able to link this identifier to patient
identifiable details. This is necessary in order to carry
out centralized follow-up.
All study documentation is held in secure offices and
the study research team operate to a signed code of
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password-protected database by the data manager. Paper
copies of questionnaires are kept in locked cabinets in a
locked room.
Any previously collected data are retained for patients
who subsequently withdraw from the trial. This data is
anonymized and kept confidential.
Trial documentation will be kept for 15 years after
publication of the final paper/report from this study.
Randomization form
This provides baseline information and is required in
order to randomize the patient.
Two-week/discharge form
At 2 weeks after randomization or at discharge or death
(whichever occurs first) the discharge/2-week form is
completed by the responsible neurosurgeon or research
nurse. This form records the date, the event that triggers
the form, and the patient’s status at that time, whether the
patient has had surgery (and why if randomized to initial
conservative treatment or why not if randomized to early
surgery), the patient’s GCS and localizing features for the
5 days following randomization, the occurrence of any
adverse events (including death, pulmonary embolism,
deep vein thrombosis, surgical site infection) following
randomization, past medical history, and status prior to the
ictus. This form together with copies of the randomization
CT scan and the 5-day post-randomization CT scan (as
detailed below) should be sent to the STITCH(Trauma)
office at the Neurosurgical Trials Unit in Newcastle UK
within 2 weeks. The data manager enters the data into the
anonymized password-protected database.
CT scans
Copies of two CT scans are required: the diagnostic CT
scan prior to randomization and a 5-day scan. All
patients have undergone a diagnostic CT scan as stand-
ard practice. The 5-day scan is performed between 3 and
7 days after randomization. Many patients receive this as
part of standard treatment and the study accepts and
uses any scan taken for clinical purposes during this
period. Only patients who do not receive such a scan
during this period require an additional scan.
The preferred scan is a CT scan with volume acquisi-
tion 32 × 0.5 mm (or equivalent); 120 Kv 400 mA (or
equivalent); 220 FOV. The angle should be parallel with
the anterior cranial fossa, coverage from base of skull to
vertex; reconstruct 5 mm whole head, soft tissue filter.
The preferred method of sending CT scans is in
DICOM compatible format. DICOM images (on separate
CDs for the two time points) are sent anonymized with
patient identifier. They are checked by the data manager
initially on receipt at the STITCH(Trauma) office toensure that the hematoma characteristics at random-
ization conform to the required inclusion criteria. Where
protocol deviations are suspected the data manager
arranges for the scan to be viewed by a trained reader im-
mediately and if their suspicions are confirmed the cen-
ter is contacted immediately to prevent repetitions.
The data manager loads the scans into a specialized
password-protected scan management program. The
scans are then allocated a separate randomly created
identifier by the data manager, so that it is not possible
for the reader to identify the before and after scans of
the same patient. The scans are stored in locked cabi-
nets. A separate list identifying patient identifier and
scan identifier is kept by the data manager.
The CT scans are analyzed subsequently by trained
readers using the scan management program. Their
passwords only give access to scans blinded to treatment
group and patient identity following a defined protocol.
Follow-up
Postal follow-up occurs at 6 and 12 months using ques-
tionnaires translated into the appropriate language. The
patient’s GP (in the UK) or consultant (outside the UK)
is contacted at 4.5 months to check that the patient is
alive and to confirm his/her place of residence. At this
time the GP/Consultant is also requested to complete a
major adverse events form. The 6-month outcome ques-
tionnaire is mailed to the patient at 5 months for com-
pletion by the patient or relative if the patient is unable
to complete it themselves. If necessary a reminder is sent
at 6 months and telephone follow-up at 7 months by
‘blinded’ clerical or nursing staff to enhance response
rates. In countries where the postal system is poor,
patients are requested to attend a follow-up clinic at
which the questionnaire is distributed and collected. In
countries where literacy or language/dialect are prob-
lematic a ‘blinded’ interviewer administers the question-
naire. This methodology has been used to good effect in
previous studies: STICH and STICH II.
The costs associated with surgical treatment (theater
time, consumables, overheads) will be collected from
published resources and local cost surveys undertaken
by the study health economist. Length of stay, healthcare
resource use outside of hospital, together with pro-
ductivity costs arising from absence from work, and
additional costs for family members through extra
caring responsibilities are collected using the additional
3-month postal questionnaire and extended 6-month
and 12-month postal questionnaires in the UK. Conse-
quences will be measured by combining data on quality
of life with survival to generate Quality Adjusted Life
Years. This will include measurement of healthcare
costs, quality of life (EQ-5D), work absence (WHO
Health and Performance Questionnaire-Clinical Trial
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Choice Experiment developed by HERU). EQ-5D and
survival are collected for all patients by the postal out-
come questionnaires in order to generate QALYS for the
whole study and for a UK-only analysis (Figure 1).
Serious adverse events
Serious adverse events (SAEs) are recorded on the
Major Adverse Events form. Serious adverse events are
adverse experiences that result in any of the following
outcomes: death; life-threatening events; requirement
for inpatient hospitalization or prolongation of existing
hospitalization; or persistent or significant disability or
incapacity.
All SAEs should be reported to the STITCH Office
within 7 days of the local investigator becoming aware
of the event and to the local ethics committee or other
regulatory bodies as required.
Outcome measures
Primary: Unfavorable outcome will be death or severe
disability which will be defined using a prognosis based
eight-point Glasgow Outcome Scale/ Modified Rankin
Scale [3,12].Screening
Pre-
randomisation
<
h
Diagnostic CT X
INR X
Informed consent X
Baseline data X
Surgery (if randomised to 
early surgery)
ICP (if monitored)
GCS/Focal signs
CT scan
Hospital data
GOS
Rankin
EQ-5D
Carer Activities (UK only)
Resource Use (UK only)
* 14 days or at death or discharge whichever occurs 
earliest
UK only
Surgical 
group only
ICP monitored subgr
Figure 1 Chart showing study timetable for treatment of patients.Secondary: Rankin, EQ-5D, Mortality, Survival, Major
Adverse Events (death, pulmonary embolism or deep
vein thrombosis, infection, re-hemorrhage), QALYs, total
healthcare costs, social costs.
The Glasgow Outcome Scale is the specific measure for
head injury and the eight-point scale provides more sensi-
tivity than the five-point scale. For patients with a very
poor prognosis an outcome of good recovery, moderate
disability or upper severe disability would be regarded as a
favorable outcome. For patients with a better prognosis fa-
vorable outcome would be good recovery or moderate dis-
ability. A structured postal version has been developed
[13]. The Rankin scale is widely used as a functional out-
come measure in stroke and allows comparison of results
between this study of patients with traumatic ICH and
studies of patients with spontaneous ICH. EQ-5D is the
standard measure of quality of life incorporating a utility
value and has been developed in many languages.
Sample size
Previous studies have suggested a favorable outcome in
the non-operated group of about 40% and a favorable
outcome in the surgical group of about 60% to 70%.
However this was in observational studies. Assuming a12 
ours
Day 1 
-5
Day 5 
(+/ -2)
Day
14 *
Day 
90 
Day 
180 
Day 
360
X
X
X
X
X
X X X
X X
X X X
X X X
X X X
oup
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on the Glasgow Outcome Scale) of 50% from conserva-
tive treatment a total sample size of 776 would be
required to show a 10% benefit (that is, 50% vs. 60%)
from surgery (2p <0.05) with 80% power. A safety mar-
gin of 9.5% is built in to allow for loss to follow-up mak-
ing a total sample size of 840 to be recruited and
randomized (420 per arm).
In order to achieve this sample size in a reasonable
time span and to provide robust evidence it is necessary
to recruit patients from outside UK. In England and
Wales there are only 30 neurosurgical units and only
one-third of these participate in randomized controlled
trials. Experience with interested neurosurgical centers
in previous studies has shown that about 25% of
recruited centers fail to recruit any patients and a fur-
ther 25% only recruit one or two patients. The best
recruiting centers will recruit about 10 patients per year
so to complete patient recruitment within the timescale
we will approach at least 150 centers.
Loss to follow-up is kept as low as possible. In the
STICH study the loss was about 5%. In STITCH
(TRAUMA) the population is a little younger and likely
to be more mobile; however, we carry out more checks
and implement procedures that we have developed to
minimize loss to follow-up. Methods of follow-up are
adapted to those most likely to be successful within each
country and center according to local population and
care characteristics. Centers that achieve poor follow-up
are monitored closely and may be withdrawn from the
study if they are unable to locate patients for 6-month
follow-up. We require residence in any study country as
an eligibility criterion so patients who suffer a head in-
jury whilst on holiday and might be lost to follow-up are
not eligible and are not included.
Blinding
It is not possible to blind either patients or treating sur-
geons as to when the patient has had surgery or whether
they have had surgery. To minimize possible sources of
bias, randomization is undertaken centrally, thus ensur-
ing concealment of allocation from the enrolling clin-
ician, patient, and relatives. All patients randomized, for
whom outcome data can be collected, will be included
in the analysis by intention to treat. The multidisciplin-
ary team in the co-ordinating center and the principal
investigators will be blinded to the results until after the
data set is locked following receipt of the final outcome
questionnaire. Only the data manager will have access to
‘unblinded’ data.
Statistical analysis
Analysis will be on an ‘intention-to-treat’ basis. The pri-
mary analysis will be a simple categorical frequencycomparison using the uncorrected chi-squared test for
prognosis-based [13,14] favorable and unfavorable out-
comes at 6 months. Patients with a good prognosis will
be categorized as having a favorable outcome if they
achieve good recovery or moderate disability on the
Glasgow Outcome Scale. Patients with a poor prognosis
will be categorized as having a favorable outcome if
they achieve good recovery, moderate disability, or upper
severe disability on the extended Glasgow Outcome
Scale. Logistic regression analysis will be undertaken to
adjust for covariates. Secondary outcomes will also be
analyzed using the prognosis based method as specified
in STICH [3].
Given the likelihood of a proportion of crossovers, a
secondary sensitivity analysis of per-treatment as well as
an analysis considering crossovers to surgery as failed
medical treatment will be undertaken. Further analyses
of factors that drive crossovers as well as per-protocol
and per-treatment analyses will be conducted to investi-
gate the effect of crossovers.
Any subgroup analyses will be based on tests of inter-
action. The predefined subgroups (all of which will be
considered exploratory, since the study is not powered
for formal subgroup analyses) include the following: age;
hematoma volume; Glasgow Coma Score; time from in-
jury to randomization; severity of neurological deficit;
pupils equal and reacting or not; planned method of
hematoma removal; patients with invasive monitoring
(ICP/CPP); anticoagulation status.
Interim analyses are conducted at intervals predeter-
mined by the DMEC. The results of interim analyses are
strictly confidential and the trial will only be stopped
early if one or other treatment policy shows an advan-
tage at a very high significance level, or if recruitment
rates are unexpectedly low.
Deterministic and probabilistic sensitivity analyses will
be conducted to consider the importance of individual
parameters and assumptions in determining cost-effect-
iveness. This will include the effect of time horizon, vari-
ation in unit costs across centers, and quality of life
values. Bootstrapped-generated differences in costs and
effectiveness between strategies will be computed, and
results presented using cost-effectiveness acceptability
curves (CEACs).
Receiver-operating curves will be used to investigate
appropriate thresholds of ICP and CPP for treatment as
they have been used previously in pediatric studies [15].
Ethical issues and research governance
Risks and anticipated benefits for trial participants and
society
Risks and benefits for trial participants - the risks from
undergoing surgery include risks of complications due to
undergoing a general anesthetic and surgery; however,
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to the risks of delaying surgery. Only those patients for
whom the treating clinician, patient, and relative are in
equipoise regarding early surgery vs. conservative man-
agement are enrolled in the trial.
Anticipated benefit for society is that of improved out-
come for patients in the future. The results will inform
decision-making, permitting evidence-based policies to
be developed for the management of traumatic ICH. If
surgery is shown to be ineffective, then cost savings can
be made by avoiding surgery. If surgery is shown to be
effective, then better outcomes will be achieved for the
patient together with reduced rehabilitation and recov-
ery costs to the NHS and the patients and their families.
Trial committees
Data monitoring and ethics committee
In order to monitor accumulating data on patient safety
and treatment benefit an independent data monitoring and
ethics committee (DMEC) was established. The DMEC
considers data from interim analyses and reports to the
Trial Steering Committee. A written charter was developed
and agreed prior to the first DMEC meeting. Interim ana-
lyses are strictly confidential and the committee will only
recommend stopping the trial early if one or other treat-
ment shows an advantage at a very high significance level.
Management committee
This group meets weekly to monitor progress and
compliance.
Trial steering committee
Independent oversight of the study is provided by a Trial
Steering Committee (TSC) which meets every 6 months.
The Trial Steering Committee provides overall supervi-
sion of the trial on behalf of the HTA. It considers pro-
gress of the trial (in particular, success in site and
patient recruitment), adherence to the protocol, patient
safety, and consideration of new information. The trial is
conducted according to the standards set out in the
MRC Guidelines for Good Clinical Practice. A written
charter was developed and agreed prior to the first TSC
meeting.
Roles and responsibilities
Principal investigators and trial team
Professor A D Mendelow has overall responsibility for
the trial. He is also responsible for disseminating infor-
mation about the trial, recruiting centers, and for writing
and publication of the results.
Dr B A Gregson is responsible for the overall statistical
validity of the trial and day-to-day conduct of the trial
including availability of coordinating advice in Newcastle.
She is also responsible for preparation of protocols andquestionnaires, for MREC application, for preparing an-
nual reports to HTA and Ethics committees, for commu-
nication and dissemination of information to centers, for
monitoring centers, for data analysis, and for writing up
of results.
Mr P Mitchell is responsible for recruiting centers and
for analysis and publication of results.
Professor Elaine McColl is responsible for ensuring
that the trial is run according to GCP guidelines and
advises on overall trial conduct and project management.
Dr Iain Chambers is responsible for ensuring the qual-
ity of ICP and CPP data collected and for the analysis of
this data.
Dr Paul McNamee is responsible for the economic val-
idity of the trial; he is responsible for the design of the
economic component of the trial and over sees the eco-
nomic data collection and analysis.
The trial manager is responsible for ensuring ethics
approvals and agreements are in place in all centers, ne-
gotiating as required between contracts personnel, to
maintain a website to encourage site and patient recruit-
ment, to provide reports to trial management and steer-
ing committees, to the funder and to the research ethics
committees as required, to monitor compliance and to
communicate with the centers.
The data manager is responsible for maintaining com-
puterized databases containing all data related to the
trial, for the quality of computerized information, for
conducting preliminary analyses and preparing reports
for the DMEC, for providing information to the appli-
cants, and for preparing monthly newsletters.
The trial secretary is responsible for all trial correspond-
ence in relation to the trial, for sending postal question-
naires and reminders, for the organization of investigator
meetings and travel for monitoring, maintaining telephone
and fax communications, preparing quarterly newsletters
and publications, and reimbursing centers.
The health economist is responsible for undertaking
the collection and analysis of economic data.
Responsibilities of national investigators
In countries with multiple centers one center investiga-
tor fulfills the role of National Investigator. National
investigators are responsible for obtaining national eth-
ical approval and other permissions as required, for
ensuring that documentation is translated from English
as required, for identifying suitable centers within their
country, for encouraging recruitment, and acting as a
liaison person between the STITCH(TRAUMA) team
and the center if required.
Responsibilities of center investigators
Each center agrees to follow the protocol. They provide
and update when necessary full address and contact
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collaborator who is responsible for the conduct of the
trial in his/her center and in particular for: local ethical
applications and applications for other permissions as
required; disseminating information about the trial
within the center; maintaining local trial documentation,
including site files, delegation logs, et cetera; identifying
suitable patients; ensuring all case report forms are com-
pleted and returned to the STITCH office in Newcastle
expeditiously; ensuring copies of CT scans are provided
to STITCH office in Newcastle expeditiously; ensuring
follow-up is obtained in the center; attending investiga-
tor meetings (in person or via video- or teleconference);
facilitating center monitoring; commenting on the final
report.
Centers receive a monitoring visit as required either
after recruiting at least 10 patients or if there is a per-
ceived need (Additional file 1).
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Address: STITCH(Trauma), Neurosurgical Trials Unit,
3–4 Claremont Terrace, Newcastle University, Newcastle
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